Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome

Journal of the American Academy of Dermatology

Volumn 56, Issue 4, 2007, Pages 580-583

  Querfeld, Christiane ^a,e   Rosen, Steven T ^b,e   Guitart, Joan ^a,e   Rademaker, Alfred ^c,e   Foss, Francine ^f   Gupta, Rohit ^d   Kuzel, Timothy M ^b,e  

^a Departments of Dermatology

^b Medicine   (United States)

^c Division of Hematology/Oncology

^d Department of Pathology ^*

^e NORTHWESTERN UNIVERSITY   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; EDEMA; FATIGUE; FEMALE; HELPER CELL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOPHENOTYPING; INFECTION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEZARY SYNDROME; SIDE EFFECT; SKIN TOXICITY; SWEATING; T LYMPHOCYTE SUBPOPULATION; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SEZARY SYNDROME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33947106539     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.08.067     Document Type: Article

References (22)

1. Querfeld C., Guitart J., Kuzel T.M., and Rosen S.T. Primary cutaneous lymphomas: a review with current treatment options. Blood Rev 17 (2003) 131-142
2. Lee B.N., Duvic M., Tang C.K., Bueso-Ramos C., Estrov Z., and Steuben J.M. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T-cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 6 (1999) 79-84
3. Vowels B.R., Cassin M., Vonderheid E.C., and Rook A.H. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 99 (1992) 90-94
4. + T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 19 (2001) 4322-4329
5. + T-cells from CD45RA to CD45RO is accompanied by cell activation and proliferation. Cytometry 19 (1995) 343-353
6. Hodge S., Hodge G., Flower R., and Han P. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood. Scand J Immunol 51 (2000) 67-72
7. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
8. Malek T.R., and Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4 (2004) 665-674
9. Berger C., Tigelaar R., Cohen J., Mariwalla W., Trinh J., Wang N., et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 105 (2005) 1640-1647
10. Shurin M.K., Kirkwood J.M., and Esche C. Cytokine-based therapy for melanoma: pre-clinical studies. Forum (Genova) 10 (2000) 204-226
11. Atkins M.B., Kunkel L., Sznol M., and Rosenberg S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6 Suppl (2000) S11-S14
12. Negrier S., Maral J., Drevon M., Vinke J., Escudier B., and Philip T. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 6 Suppl (2000) S93-S98
13. Nagatani T., Kin S.T., Baba N., Miyamoto H., Nakajima H., and Katoh Y. A case of cutaneous T cell lymphoma treated with recombinant interleukin 2 (rIL-2). Acta Derm Venereol 68 (1988) 504-508
14. Rybojad M., Marolleau J.P., Flageul B., Baccard M., Brandely M., Morel P., et al. Successful interleukin-2 therapy of advanced cutaneous T-cell lymphoma. Br J Dermatol 127 (1992) 63-64
15. Gisselbrecht C., Maranchini D., Pico J.L., Milpied N., Coiffier B., Divine M., et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 83 (1994) 2081-2085
16. Marolleau J.P., Baccard M., Flageul B., Rybojad M., Laroche L., Verola O., et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 131 (1995) 574-579
17. Baccard M., Marolleau J.P., and Rybojad M. Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2. Arch Dermatol 133 (1997) 656
18. Gold P.J., Thompson J.A., Lindgren C., Kern D., and Fefer A. Phase I trial subcutaneous outpatient interleukin-2 for patients with advanced mycosis fungoides. Blood 88 (1996) 191b
19. Bouaziz J.D., Ortonne N., Giustiniani J., Schiavon V., Huet D., Bagot M., et al. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in Sézary syndrome patients. J Invest Dermatol 125 (2005) 1273-1278
20. Fumagalli L.A., Vinke J., Hoff W., Ypma E., Brivio F., and Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26 (2003) 394-402
21. - T cells. J Clin Invest 112 (2003) 1437-1443
22. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174 (2005) 2591-2601